Dr. Sachin M. Shridharani is a Harvard-educated, Johns Hopkins, trained, renowned, board-certified plastic surgeon based on Manhattan’s famed Fifth Avenue and the founder of LUXURGERY - The confluence of luxury and aesthetic surgery. His firm commitment to excellence has earned him several global accolades. Dr. S has authored over 200 publications and abstracts and is recognized as an international authority on aesthetic plastic surgery treatments and techniques. Dr. Shridharani serves as an international Global Thought Leader/Key Opinion Leader and has lectured to colleagues on nearly every continent. He serves as a Principal Investigator for clinical trials. Dr. Shridharani is frequently featured in national media outlets including The New York Times, New York Post, Cosmopolitan Magazine, Harper’s Bazaar, NBC, FOX, and ABC. Dr. Shridharani serves as the cosmetic surgery expert and is a recurrent contributor on the topic of plastic surgery and beauty for Haute Beauty.
Haute Beauty sits down with Dr. Sachin Shridharani, to talk about QWO, the world’s first and only FDA-approved injectable that effectively treats cellulite.
Photo Credit: ShutterstockDr. Shridharani is and has been involved in several of the FDA-approved clinical trials that helped gather data and information on how to safely administer QWO and improve the appearance of cellulite. To-date Dr. S has performed hundreds of injections of QWO, making him one of the most experienced injectors of QWO in the world.
“It was something that my team and I got involved with over a year ago. We really started our in-depth work about that time and there have been incredible strides made to improve the appearance of cellulite with this drug. It’s a privilege to help work on treatments that then get FDA-approved which go on to impact millions of people once commercially available,” says Dr. Shridharani.
“We already have a waitlist of patients who want to be treated,” says Dr. Shridharani. “I’m not totally surprised considering how much cellulite bothers my patients,” he adds.
HB: How is QWO going to be a game-changer in the aesthetics industry?
QWO is a game-changer in the aesthetics industry because it is the first injectable, non-surgical treatment for cellulite that has been clinically proven to reduce moderate to severe cellulite.
HB: How does it work?
QWO involves a specific type of enzyme known as collagenase, which breaks down the fibrous bands that contribute to the skin depressions and dimpling appearance of cellulite. Once these bands degrade, the skin depressions seen in cellulite dimpling are released into a smoother dermal surface. Additionally, QWO stimulates your body to produce new collagen, which further contributes to an improved complexion.
Photo Credit: ShutterstockHB: Do you think this will be the #1 treatment to treat cellulite moving forward?
QWO is the first and only FDA-approved injectable for the treatment of cellulite. It is a quick and simple solution to a problem many women have struggled with yet have never had a clinically-proven treatment for. The treatment is non-surgical and requires no downtime afterward. Dr. S has already seen remarkable results in the clinical trials he conducted with QWO as principal investigator.
HB: How is LUXURGERY awaiting the release of QWO?
As one of QWO's principal investigators during the clinical trials, Dr. Shridharani was involved early on in the treatment’s development and was so excited to co-chair Qwo’s launch events in early March by teaching thousands of peers from around the country how to safely use QWO. Dr. S has officially started treating non-clinical trial patients and has brought his expertise with injecting this innovative, cutting-edge, cellulite treatment to his patients at LUXURGERY.
For more information, visit Sachin Shridharani, MD, FACS's social media:
